- Avicanna Inc. (TSX:AVCN) has announced a large-scale medical cannabis real world evidence study through the MyMedi.ca medical cannabis care platform.
- The study will be led by Hance Clarke, MD, FRCPC, Ph.D., who is the president of The Canadian Pain Society and the Canadian Consortium for the Investigation of Cannabinoids.
- The study aims to enroll 1,000 patients across Canada to understand the potential therapeutic use of medical cannabis and potential impact of medical cannabis on pain, sleep, anxiety, depression, and epilepsy.
- Shares of Avicanna Inc. are down 2.47 per cent, trading at C$0.395 as of 12:13 pm ET.
Biopharmaceutical company Avicanna Inc. (TSX:AVCN; OTCQX:AVCNF; FSE:0NN) has announced a large-scale medical cannabis real world evidence study through the MyMedi.ca medical cannabis care platform.
The study will be led by Hance Clarke, MD, FRCPC, Ph.D., who is the president of The Canadian Pain Society and the Canadian Consortium for the Investigation of Cannabinoids.
According to a news release Monday, the prospective, non-interventional, observational study aims to enroll 1,000 patients across Canada to understand the potential therapeutic use of medical cannabis and potential impact of medical cannabis on pain, sleep, anxiety, depression, and epilepsy. “Utilizing validated questionnaires, the study seeks to understand the potential impact of various medical cannabis products and evaluate the change in use of concomitant medication over a 24-week duration,” the release stated.
“I am pleased that Avicanna has stepped up to support this important work. We must continue to gather data and better understand what effects these cannabis products are having on Canadian patients that are approaching cannabis for therapeutic benefit,” Clarke said in a statement.
Originally initiated by Medical Cannabis by Shoppers, which closed last year, the study was part of Avicanna’s efforts to provide continuation of care to the platforms’ patients and the advancement of medical research. Avicanna’s medical cannabis care platform MyMedi.ca will provide the necessary infrastructure, patient support, and education for all participating healthcare providers nationwide.
“MyMedi.ca medical cannabis care platform was established with a number of goals that included, access to medical cannabis, providing patient support and education, and facilitating research on cannabinoid medicines,” Karolina Urban, Avicanna’s executive vice president of medical affairs, said in a statement. “We are excited to support the study and hope that the results of this study will provide data, evidence, and increase our understanding of the potential impacts of medical cannabis across a range of conditions that may facilitate the incorporation of medical cannabis into standard of care.”
Participating patients will have access to the MyMedi.ca platform’s products including Avicanna’s RHO Phyto formulary in addition to products from select licensed producers that are supporting the study.
Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of cannabinoid-based products and formulations for the global medical and pharmaceutical market segments.
Shares of Avicanna Inc. (TSX:AVCN) are down 2.47 per cent, trading at C$0.395 as of 12:13 pm ET.
Join the discussion: Find out what everybody’s saying about this cannabis stock on the Avicanna Inc. Bullboard, and check out the rest of Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
(Top photo: Avicanna Inc.)